Efficacy of aPseudomonas aeruginosaSerogroup O9 Vaccine

Abstract

ABSTRACTThere are currently no approved vaccines against the opportunistic pathogenPseudomonas aeruginosa. Among vaccine targets, the lipopolysaccharide (LPS) O antigen ofP. aeruginosais the most immunodominant protective candidate. There are twenty different O antigens composed of different repeat sugars structures conferring serogroup specificity, and ten are found most frequently in infection. Thus, one approach to combat infection byP. aeruginosacould be to generate immunity with a vaccine cocktail that includes all these serogroups. Serogroup O9 is one of the ten serogroups commonly found in infection, but it has never been developed into a vaccine, likely due, in part, to the acid labile nature of the O9 polysaccharide. Our laboratory has previously shown that intranasal administration of an attenuatedSalmonellastrain expressing theP. aeruginosaserogroup O11 LPS O antigen was effective in clearing and preventing mortality in mice following intranasal challenge with serogroup O11P. aeruginosa. Consequently, we set out to develop aP.aeruginosaserogroup O9 vaccine using a similar approach. Here we show thatSalmonellaexpressing serogroup O9 triggered an antibody-mediated immune response following intranasal administration to mice and that it conferred protection fromP. aeruginosaserogroup O9 in a murine model of acute pneumonia.